Derek Maclean

Derek Maclean has a strong background in pharmaceutical sciences and chemistry research. Derek started their career at Parke-Davis, where they worked as a Scientist and focused on medicinal chemistry development. Derek then moved on to Affymax, where they worked as a Senior Scientist and was responsible for integrating synthetic chemistry, biology, and engineering for drug discovery applications. At GlaxoSmithKline, they held the role of Senior Scientist and led chemistry activities for Glaxo's Imaging Initiative. Derek then joined CTI Molecular Imaging as the Director of Research, where they directed a cross-disciplinary research effort in medical imaging technology. Derek later worked at KAI Pharmaceuticals as the Senior Director of Chemistry, leading research and development activities. Derek continued their career at Amgen, where they served as the Director of Process Engineering and contributed to the acquisition of KAI Pharmaceuticals. Derek then joined Relypsa as the Vice President of Discovery Chemistry, leading chemistry research activities and establishing a facility for polymer synthesis. Currently, they hold the position of Vice President of Pharmaceutical Sciences at Applied Molecular Transport, where they focus on formulation development and manufacturing leadership for advanced biological therapeutics. Overall, Derek Maclean has a diverse range of experiences in the pharmaceutical industry, with a strong emphasis on chemistry research and leadership roles.

Derek Maclean's education history began in 1984 when they attended the University of Aberdeen for their Bachelor of Science (BSc) degree in Chemistry. Derek studied there for four years, completing their degree in 1988. Following this, they pursued further studies at The University of Edinburgh, where they obtained their Doctor of Philosophy (PhD) degree in Chemistry from 1988 to 1991.